Fig. 2: Effectiveness of Bacillus spore nasal spray in improving clinical RSV symptoms. | Communications Medicine

Fig. 2: Effectiveness of Bacillus spore nasal spray in improving clinical RSV symptoms.

From: Nasal-spraying Bacillus spore probiotics for pneumonia in children with respiratory syncytial virus and bacterial co-infections: a randomized clinical trial

Fig. 2: Effectiveness of Bacillus spore nasal spray in improving clinical RSV symptoms.

Treatment duration (number of days to resolve symptoms) (a1–k1) and Kaplan–Meier analysis of estimated percentage (%) of symptomatic patients (a2–k2) observed over treatment duration for symptoms of pneumonia in the Control (dashed lines) and Navax (solid lines) groups. The distribution of the number of antibiotics prescribed in the first two days (l1), duration of antibiotic treatment with 1- and 2-type antibiotics (l2), and total antibiotic treatment days (l3) prescribed for children with pneumonia in the Control and Navax groups. Statistical significance was evaluated using the Mann–Whitney test. Median values with 95% CI for each group and the median difference between the two groups are shown in panels a–k. Error bars in panels l2–l3 indicate the upper extreme (Q3 + 1.5 × IQR) and the lower extreme (Q1 – 1.5 × IQR). The significance level for all analyses was set at p < 0.05. Sample size: n = 50 biologically independent patients in the Control group and n = 51 in the Navax group.

Back to article page